Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652572 · ClinicalTrials.gov registry record · Phase 1
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers
A Phase 1 study of Venous Leg Ulcer, sponsored by Xequel Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT02652572: Completed Phase 1 study of Venous Leg Ulcer, sponsored by Xequel Bio.
NCT02652572 is a Phase 1 study of Venous Leg Ulcer that has completed, run by Xequel Bio. The registered enrollment target is 10 participants, below the 245-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02652572, a Phase 1 study of Venous Leg Ulcer, has completed, sponsored by Xequel Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' venous leg ulcers.
Conditions Studied
Interventions
- DRUG Granexin
Study Locations (3)
Georgia
- Aiyan Diabetes Center - Augusta
South Carolina
- Spartanburg Regional Healthcare System - Spartanburg
Virginia
- Salem VA Medical Center - Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
What the finished NCT02652572 record still lists
NCT02652572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 245-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Granexin is the first listed.
NCT02652572 reports a single indexed study location in Georgia, South Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT02652572 about?
NCT02652572 is a clinical study titled "Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers". The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' venous leg ulcers.
What is the current status of trial NCT02652572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-09. Estimated completion is 2018-05.
What conditions does trial NCT02652572 study?
This clinical trial studies the following conditions: Venous Leg Ulcer.
What interventions are being tested in trial NCT02652572?
The interventions under investigation include: Granexin (DRUG).
Who is sponsoring clinical trial NCT02652572?
This trial is sponsored by Xequel Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02652572 being conducted?
This trial has 3 study locations across Georgia, South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Leg Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02652572's enrollment target sits among peer trials
10 35th of 35 the lowest of 35 other Venous Leg Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Leg Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
RECRUITING · Phase 4
-
Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia